These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 34512637)

  • 1. Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation.
    Proschmann U; Haase R; Inojosa H; Akgün K; Ziemssen T
    Front Immunol; 2021; 12():715195. PubMed ID: 34512637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment.
    Højsgaard Chow H; Petersen ER; Olsson A; Hejgaard Laursen J; Bredahl Hansen M; Oturai AB; Soelberg Sørensen P; Bach Søndergaard H; Sellebjerg F
    Mult Scler Relat Disord; 2024 Aug; 88():105701. PubMed ID: 38889559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer of natalizumab into breast milk in a mother with multiple sclerosis.
    Baker TE; Cooper SD; Kessler L; Hale TW
    J Hum Lact; 2015 May; 31(2):233-6. PubMed ID: 25586712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Fox RJ; Cree BAC; de Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Singh CM; Altincatal A; Belviso N; Avila RL; Ho PR; Su R; Engle R; Sangurdekar D; de Moor C; Fisher E; Kieseier BC; Rudick RA
    Neurology; 2024 May; 102(9):e209357. PubMed ID: 38648580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder.
    Ciplea AI; Langer-Gould A; de Vries A; Schaap T; Thiel S; Ringelstein M; Gold R; Hellwig K
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32327455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases.
    LaHue SC; Anderson A; Krysko KM; Rutatangwa A; Dorsey MJ; Hale T; Mahadevan U; Rogers EE; Rosenstein MG; Bove R
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32461351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Johnsson M; Farman HH; Blennow K; Zetterberg H; Malmeström C; Axelsson M; Lycke J
    Mult Scler; 2022 Nov; 28(13):2070-2080. PubMed ID: 35856574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
    Fissolo N; Pignolet B; Rio J; Vermersch P; Ruet A; deSèze J; Labauge P; Vukusic S; Papeix C; Martinez-Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Bourre B; Defer G; Montalban X; Brassat D; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(4):. PubMed ID: 33903203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants.
    Bove R; Hellwig K; Pasquarelli N; Borriello F; Dobson R; Oreja-Guevara C; Lin CJ; Zecevic D; Craveiro L; McElrath T; Vukusic S
    Mult Scler Relat Disord; 2022 Aug; 64():103963. PubMed ID: 35753176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study.
    Cuello JP; Martínez Ginés ML; Kuhle J; García Domínguez JM; Lozano Ros A; Romero Delgado F; Higueras Y; Meldaña Rivera A; Goicochea Briceño H; García-Tizon Larroca S; De León-Luis J; Michalak Z; Barro C; Álvarez Lafuente R; Medina Heras S; Fernández Velasco JI; Tejeda-Velarde A; Domínguez-Mozo MI; Muriel A; de Andrés C; Villar LM
    Eur J Neurol; 2019 Sep; 26(9):1200-1204. PubMed ID: 30977955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neurofilament levels and patient-reported outcomes in multiple sclerosis.
    Galetta K; Deshpande C; Healy BC; Glanz B; Ziehn M; Saxena S; Paul A; Saleh F; Collins M; Gaitan-Walsh P; Castro-Mendoza P; Weiner HL; Chitnis T
    Ann Clin Transl Neurol; 2021 Mar; 8(3):631-638. PubMed ID: 33492760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis.
    Reinert MC; Benkert P; Wuerfel J; Michalak Z; Ruberte E; Barro C; Huppke P; Stark W; Kropshofer H; Tomic D; Leppert D; Kuhle J; Brück W; Gärtner J
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32404429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab during pregnancy and lactation.
    Proschmann U; Thomas K; Thiel S; Hellwig K; Ziemssen T
    Mult Scler; 2018 Oct; 24(12):1627-1634. PubMed ID: 28857686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients.
    Dalla Costa G; Martinelli V; Moiola L; Sangalli F; Colombo B; Finardi A; Cinque P; Kolb EM; Haghikia A; Gold R; Furlan R; Comi G
    Ann Neurol; 2019 Apr; 85(4):606-610. PubMed ID: 30761586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis.
    Proschmann U; Inojosa H; Akgün K; Ziemssen T
    Front Neurol; 2021; 12():650530. PubMed ID: 33935948
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic value of neurofilament light chain in natalizumab therapy for different phases of multiple sclerosis: A systematic review and meta-analysis.
    Liu N; Sun M; Zhang W; Sun J; Gong P; Wang H; Wang M
    J Clin Neurosci; 2022 Jul; 101():198-203. PubMed ID: 35617924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.